Direct comparison
EMA vs. FDA: Trial & Approval Pathways
EMA vs. FDA compared: centralised vs. national approval routes, CTIS vs. IND submissions, and PRIME vs. Breakthrough Therapy expedited pathways.
Side-by-side comparison
| Dimension | EMA (European Medicines Agency) | FDA (U.S. Food and Drug Administration) |
|---|---|---|
| Jurisdiction / structure | EU decentralised agency; coordinates national authorities toward one EU-wide decision made by the European Commission | Single U.S. federal agency (HHS); is itself the authorising body, no intermediate national layer |
| Marketing authorisation routes | Centralised Procedure (EU-wide, mandatory for biotech/oncology/orphan/ATMPs), Decentralised Procedure, Mutual Recognition Procedure, or purely national | Single national route: New Drug Application (NDA) for drugs, Biologics License Application (BLA) for biologics |
| Clinical trial application system | Clinical Trials Information System (CTIS) — sole mandatory EU route since 31 Jan 2025, under the EU Clinical Trials Regulation (536/2014) | Investigational New Drug (IND) application under 21 CFR Part 312 |
| Trial submission model | One CTIS submission covers all participating member states; Reporting Member State leads joint Part I assessment, each state assesses its own Part II items | Single submission to a single agency; default 30-day FDA review window with possible clinical hold |
| Standard review timeline | 210 days (CHMP scientific assessment, centralised procedure) | 10-month standard review goal (NDA/BLA) |
| Earliest-stage development support | PRIME (PRIority MEdicines) — launched 2016, early CHMP rapporteur + enhanced scientific advice, feeds into accelerated assessment | Breakthrough Therapy Designation — created by FDASIA (2012), intensive FDA guidance + eligibility for rolling review |
| Shortened review pathway | Accelerated assessment — review shortened from 210 to 150 days | Priority Review — review goal shortened from 10 to 6 months |
| Approval on incomplete data | Conditional marketing authorisation — approval on less complete data with binding post-authorisation obligations | Accelerated Approval — approval via a surrogate/intermediate endpoint plus a required post-marketing confirmatory trial |
| Development-facilitation-only pathway | No separately named equivalent — functionally folded into PRIME | Fast Track — more frequent FDA interaction plus rolling submission |
| Orphan/rare disease designation | Orphan Medicinal Product designation (EU orphan regulation) | Orphan Drug Designation (Orphan Drug Act) |
| Data/market exclusivity | “8+2+1” framework: 8 years data exclusivity + 2 years market exclusivity + possible 1 extra year for a significant new indication | 5 years (NCE, small molecules) or 12 years (biologics, under BPCIA); orphan exclusivity separately runs 7 years, concurrent not additive |
| Post-marketing safety database | EudraVigilance, under the EMA's Good Pharmacovigilance Practices (GVP) framework | FDA Adverse Event Reporting System (FAERS) |
Common questions
FAQ
Does getting PRIME designation from EMA guarantee Breakthrough Therapy Designation from FDA, or vice versa?+
No. The two programs have different legal bases and are assessed independently — published analyses of paired applications have found the agencies reach concordant grant/deny outcomes in roughly two-thirds of cases, meaning a meaningful share of products are designated by one agency and not the other. Sponsors need to apply to, and satisfy, each program separately.
Can a single clinical trial protocol be submitted once for both the EU and the US?+
No. A trial running sites in both regions needs a CTIS submission (coordinated through a Reporting Member State) for the EU sites and a separate IND to FDA for the US sites, governed by different regulations (the EU Clinical Trials Regulation vs. 21 CFR Part 312) on different statutory clocks.
Is EMA's accelerated assessment the same thing as FDA's Accelerated Approval?+
No, despite the similar name. EMA's accelerated assessment only shortens the review clock (210 to 150 days) for a complete, standard data package. FDA's Accelerated Approval is a different mechanism: approval based on a surrogate or intermediate endpoint before full clinical-benefit data exist, subject to a required post-marketing confirmatory trial. The EMA mechanism closest in substance to Accelerated Approval is conditional marketing authorisation, not accelerated assessment.
Going deeper
